Vasoactive intestinal polypeptide and its receptor changes in human temporal lobe epilepsy.

de Lanerolle NC, Gunel M, Sundaresan S, Shen MY, Brines ML, Spencer DD

Brain research1 Jul 1995Cited by 28 (Europe PMC)

PMID7583284DOI10.1016/0006-8993(95)00365-wPepBankPUB-07583284

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyMechanism
In hippocampi from epilepsy patients, the distribution of the body's own VIP immunoreactivity showed no obvious change compared with the other patient groups.
In plain wordsIn human epilepsy brain tissue, the body's own VIP showed no obvious change in where it was found.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP immunoreactivity distribution in hippocampus
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Immunocytochemical localization of VIP shows no obvious change in the distribution patters of VIP immunoreactivity in the patient groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The distribution of the VIP receptor in the human hippocampus was studied by receptor autoradiography
Summary · context
was examined in hippocampi surgically removed from patients with medically intractable temporal lobe epilepsy (TLE) and hippocampi obtained at autopsy from neurologically normal subjects.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0758328404

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In human hippocampi from autopsy and from epilepsy patients with temporal lobe lesions, VIP receptor binding was highest in the dentate molecular layer and lower in the CA fields and subiculum.
In plain wordsIn human brain tissue, binding sites for VIP were most dense in the dentate molecular layer of the hippocampus.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP receptor binding distribution in hippocampus
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
In the autopsy hippocampi and hippocampi from TLE patients with extrahippocampal temporal lobe lesions [125I]VIP binding was highest in the dentate molecular layer, with lower levels in the fields of Ammon's Horn (CA fields) and the subiculum.
2 context sentences(design, population, supporting numbers)
Summary · context
The distribution of the VIP receptor in the human hippocampus was studied by receptor autoradiography
Summary · context
was examined in hippocampi surgically removed from patients with medically intractable temporal lobe epilepsy (TLE) and hippocampi obtained at autopsy from neurologically normal subjects.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0758328401
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In hippocampi from epilepsy patients with considerable neuronal loss and no temporal lobe lesions, VIP receptor binding was significantly raised in all CA fields and the subiculum.
In plain wordsIn human epilepsy brain tissue with nerve cell loss, there were more binding sites for VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP receptor binding in hippocampi with neuronal loss
Study
n: not reported in source
Comparator
Autopsy hippocampi from neurologically normal subjects
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
In hippocampi from patients with no temporal lobe lesions but considerable hippocampal neuronal loss there were significant elevations in the levels of ligand binding in all CA fields and the subiculum.
2 context sentences(design, population, supporting numbers)
Summary · context
The distribution of the VIP receptor in the human hippocampus was studied by receptor autoradiography
Summary · context
was examined in hippocampi surgically removed from patients with medically intractable temporal lobe epilepsy (TLE) and hippocampi obtained at autopsy from neurologically normal subjects.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0758328402
04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In hippocampi from epilepsy patients, VIP receptor binding density in all CA fields was strongly negatively correlated with neuronal numbers.
In plain wordsIn human epilepsy brain tissue, more VIP binding sites were linked to fewer nerve cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCorrelation of VIP receptor binding with neuronal numbers
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Ligand binding densities in all CA fields of the patient hippocampi were strongly negatively correlated with neuronal numbers.
2 context sentences(design, population, supporting numbers)
Summary · context
The distribution of the VIP receptor in the human hippocampus was studied by receptor autoradiography
Summary · context
was examined in hippocampi surgically removed from patients with medically intractable temporal lobe epilepsy (TLE) and hippocampi obtained at autopsy from neurologically normal subjects.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0758328403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.